

# Guy Boivin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8630293/publications.pdf>

Version: 2024-02-01

261  
papers

14,571  
citations

15504

65  
h-index

25787

108  
g-index

271  
all docs

271  
docs citations

271  
times ranked

12165  
citing authors

#	ARTICLE	IF	CITATIONS
1	Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 102-104.	1.8	10
2	Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, 116, 387-390.	3.3	2
3	Viral Interference between Respiratory Viruses. <i>Emerging Infectious Diseases</i> , 2022, 28, 273-281.	4.3	108
4	Duration of isolation and contagiousness in COVID-19 patients receiving tocilizumab and dexamethasone: a case series. <i>Infection Control and Hospital Epidemiology</i> , 2022, , 1-14.	1.8	1
5	Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells. <i>Viruses</i> , 2022, 14, 395.	3.3	26
6	Single-cell transcriptomics of the ventral posterolateral nucleus-enriched thalamic regions from HSV-1-infected mice reveal a novel microglia/microglia-like transcriptional response. <i>Journal of Neuroinflammation</i> , 2022, 19, 81.	7.2	9
7	Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. <i>Vaccine</i> , 2022, 40, 2635-2646.	3.8	6
8	The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 916-925.	3.4	11
9	In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes. <i>Antiviral Research</i> , 2022, 202, 105328.	4.1	2
10	<i>In Vitro</i> Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	18
11	Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples. <i>Journal of Infectious Diseases</i> , 2021, 223, 1052-1061.	4.0	6
12	Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review. <i>Reviews in Medical Virology</i> , 2021, 31, e2175.	8.3	4
13	Antiviral Drugs Against Herpesviruses. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 1-30.	1.6	10
14	RSV and HMPV Infections in 3D Tissue Cultures: Mechanisms Involved in Virus-Host and Virus-Virus Interactions. <i>Viruses</i> , 2021, 13, 139.	3.3	20
15	Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases. <i>Antiviral Research</i> , 2021, 188, 105046.	4.1	3
16	Genetics of symptom remission in outpatients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 10847.	3.3	7
17	Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0039021.	3.2	8
18	Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib. <i>ACS Omega</i> , 2021, 6, 16584-16591.	3.5	17

#	ARTICLE	IF	CITATIONS
19	Microglia are involved in phagocytosis and extracellular digestion during Zika virus encephalitis in young adult immunodeficient mice. <i>Journal of Neuroinflammation</i> , 2021, 18, 178.	7.2	17
20	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 924-932.	10.7	218
21	A novel bioluminescent herpes simplex virus 1 for in vivo monitoring of herpes simplex encephalitis. <i>Scientific Reports</i> , 2021, 11, 18688.	3.3	3
22	Zika virus and impact on male fertility. , 2021, , 289-298.		0
23	Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.. <i>Journal of General Virology</i> , 2021, 102, .	2.9	3
24	Avian Cell Line DuckCelt <sup>®</sup> -T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac <sup>®</sup> . <i>Vaccines</i> , 2021, 9, 1190.	4.4	6
25	DNA polymerases of herpesviruses and their inhibitors. <i>The Enzymes</i> , 2021, 50, 79-132.	1.7	4
26	Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls. <i>Clinical Infectious Diseases</i> , 2020, 71, 1438-1446.	5.8	40
27	Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains. <i>Journal of Infectious Diseases</i> , 2020, 221, 63-70.	4.0	51
28	Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection. <i>Vaccine</i> , 2020, 38, 278-287.	3.8	10
29	In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. <i>Viruses</i> , 2020, 12, 1139.	3.3	16
30	An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis. <i>Journal of Virology</i> , 2020, 94, .	3.4	21
31	Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus. <i>Microorganisms</i> , 2020, 8, 1968.	3.6	4
32	Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
33	Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000550.	3.0	21
34	Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice. <i>Antiviral Research</i> , 2020, 179, 104807.	4.1	16
35	Engineering of Live Chimeric Vaccines against Human Metapneumovirus. <i>Pathogens</i> , 2020, 9, 135.	2.8	6
36	Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	13.6	42

#	ARTICLE	IF	CITATIONS
37	Modified cyclodextrins as broad-spectrum antivirals. <i>Science Advances</i> , 2020, 6, eaax9318.	10.3	131
38	Frailty Hinders Recovery From Influenza and Acute Respiratory Illness in Older Adults. <i>Journal of Infectious Diseases</i> , 2020, 222, 428-437.	4.0	34
39	Pandemics Throughout History. <i>Frontiers in Microbiology</i> , 2020, 11, 631736.	3.5	330
40	Droplet Digital PCR and Immunohistochemistry Techniques to Detect Zika Virus in the Central Nervous System of Mice. <i>Methods in Molecular Biology</i> , 2020, 2142, 41-57.	0.9	6
41	Evaluation of pre- and post-fusion Human metapneumovirus F proteins as subunit vaccine candidates in mice. <i>Vaccine</i> , 2020, 38, 2122-2127.	3.8	12
42	Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. <i>Journal of Infectious Diseases</i> , 2019, 219, 365-374.	4.0	11
43	Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia. <i>Scientific Reports</i> , 2019, 9, 11493.	3.3	33
44	The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors. <i>Antiviral Research</i> , 2019, 170, 104561.	4.1	2
45	<i>Streptococcus pneumoniae</i> serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). <i>Vaccine</i> , 2019, 37, 5466-5473.	3.8	29
46	Antiviral Agents in Development for Zika Virus Infections. <i>Pharmaceuticals</i> , 2019, 12, 101.	3.8	50
47	Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development. <i>Vaccines</i> , 2019, 7, 164.	4.4	10
48	Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza virus. <i>Scientific Reports</i> , 2019, 9, 16616.	3.3	13
49	Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. <i>Chest</i> , 2019, 155, 69-78.	0.8	67
50	Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. <i>Antiviral Research</i> , 2019, 163, 91-105.	4.1	66
51	OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes. <i>Npj Vaccines</i> , 2019, 4, 4.	6.0	25
52	Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. <i>Journal of Infectious Diseases</i> , 2019, 220, 1302-1306.	4.0	12
53	Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada. <i>Emerging Infectious Diseases</i> , 2019, 25, 838-840.	4.3	7
54	Design and Validation with Influenza A Virus of an Aerosol Transmission Chamber for Ferrets. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 609.	2.6	5

#	ARTICLE	IF	CITATIONS
55	Human metapneumovirus activates NOD-like receptor protein 3 inflammasome via its small hydrophobic protein which plays a detrimental role during infection in mice. <i>PLoS Pathogens</i> , 2019, 15, e1007689.	4.7	13
56	Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures. <i>Frontiers in Immunology</i> , 2019, 10, 60.	4.8	44
57	The recruitment of peripheral blood leukocytes to the brain is delayed in susceptible BALB/c compared to resistant C57BL/6 mice during herpes simplex virus encephalitis. <i>Journal of NeuroVirology</i> , 2019, 25, 372-383.	2.1	4
58	Novel antiviral compounds and combination therapy for influenza viruses. <i>Virologie</i> , 2019, 23, 32-35.	0.1	0
59	Herpes simplex encephalitis in adult patients with MASP-2 deficiency. <i>PLoS Pathogens</i> , 2019, 15, e1008168.	4.7	17
60	The Nonstructural NS1 Protein of Influenza Viruses Modulates <i>TP53</i> Splicing through Host Factor CPSF4. <i>Journal of Virology</i> , 2019, 93, .	3.4	21
61	In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors. <i>Viruses</i> , 2019, 11, 6.	3.3	8
62	Molecular and epidemiologic investigation of a rhinovirus outbreak in a neonatal intensive care unit. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 245-247.	1.8	3
63	Molecular Pathway of Influenza Pan-neuraminidase Inhibitor Resistance in an Immunocompromised Patient. <i>Antiviral Therapy</i> , 2019, 24, 581-587.	1.0	6
64	HUMAN PARAINFLUENZA 2 RELATED ILLNESS AND A DEATH IN A GROUP OF CAPTIVE WESTERN LOWLAND GORILLAS (GORILLA GORILLA GORILLA). <i>Journal of Zoo and Wildlife Medicine</i> , 2019, 50, 713.	0.6	0
65	Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses. <i>Antiviral Research</i> , 2018, 154, 110-115.	4.1	6
66	Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). <i>Vaccine</i> , 2018, 36, 2166-2175.	3.8	52
67	Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections. <i>British Journal of Pharmacology</i> , 2018, 175, 388-403.	5.4	14
68	Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 232-240.	3.4	28
69	Resistance of Herpesviruses to Antiviral Agents. , 2018, , 233-267.		0
70	Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. <i>Viruses</i> , 2018, 10, 610.	3.3	24
71	Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models. <i>Antiviral Research</i> , 2018, 159, 26-34.	4.1	3
72	The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 2563-2574.	3.3	18

#	ARTICLE	IF	CITATIONS
73	Both IRF3 and especially IRF7 play a key role to orchestrate an effective cerebral inflammatory response in a mouse model of herpes simplex virus encephalitis. <i>Journal of NeuroVirology</i> , 2018, 24, 761-768.	2.1	16
74	Predominant role of IPS-1 over TRIF adaptor proteins in early innate immune response against Zika virus in mice. <i>Journal of General Virology</i> , 2018, 99, 209-218.	2.9	8
75	Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice. <i>Journal of General Virology</i> , 2018, 99, 1367-1380.	2.9	3
76	Herpesvirus DNA polymerases: Structures, functions and inhibitors. <i>Virus Research</i> , 2017, 234, 177-192.	2.2	68
77	Cell Culture Systems To Study Human Herpesvirus 6A/B Chromosomal Integration. <i>Journal of Virology</i> , 2017, 91, .	3.4	30
78	DNA vaccination protects mice against Zika virus-induced damage to the testes. <i>Nature Communications</i> , 2017, 8, 15743.	12.8	90
79	Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study. <i>Vaccine</i> , 2017, 35, 3647-3654.	3.8	26
80	Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in <i>UL56</i> and <i>UL54</i> Genes. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	17
81	A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx105.	0.9	36
82	<i>In vitro</i> Susceptibility of Geographically and Temporally Distinct Zika Viruses to Favipiravir and Ribavirin. <i>Antiviral Therapy</i> , 2017, 22, 613-618.	1.0	19
83	The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus. <i>Journal of Medical Virology</i> , 2017, 89, 2239-2243.	5.0	9
84	Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors. <i>Antiviral Therapy</i> , 2017, 22, 711-716.	1.0	5
85	The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness. <i>Antiviral Research</i> , 2017, 137, 6-13.	4.1	11
86	Droplet digital PCR to investigate quasi-species at codons 119 and 275 of the A(H1N1)pdm09 neuraminidase during zanamivir and oseltamivir therapies. <i>Journal of Medical Virology</i> , 2017, 89, 737-741.	5.0	3
87	The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. <i>Journal of Infectious Diseases</i> , 2017, 216, 405-414.	4.0	133
88	Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. <i>BMC Infectious Diseases</i> , 2017, 17, 805.	2.9	21
89	Antiviral Drug Resistance in Herpesviruses. , 2017, , 87-122.		2
90	Herpesvirus Resistance to Antiviral Drugs. , 2017, , 1185-1211.		2

#	ARTICLE	IF	CITATIONS
91	Protective role of CX3CR1 signalling in resident cells of the central nervous system during experimental herpes simplex virus encephalitis. <i>Journal of General Virology</i> , 2017, 98, 447-460.	2.9	12
92	Mutations in the fusion protein heptad repeat domains of human metapneumovirus impact on the formation of syncytia. <i>Journal of General Virology</i> , 2017, 98, 1174-1180.	2.9	13
93	In vitro and in vivo evidence of a potential A(H1N1)pdm09 antigenic drift mediated by escape mutations in the haemagglutinin Sa antigenic site. <i>Journal of General Virology</i> , 2017, 98, 1224-1231.	2.9	9
94	A Cluster of Three Cases of <i>Hantavirus</i> Pulmonary Syndrome among Canadian Military Personnel. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016, 2016, 1-4.	1.9	5
95	Structural Insight into NS5 of Zika Virus Leading to the Discovery of MTase Inhibitors. <i>Journal of the American Chemical Society</i> , 2016, 138, 16212-16215.	13.7	52
96	Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 654-662.	3.1	112
97	The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models. <i>Antiviral Research</i> , 2016, 132, 6-12.	4.1	14
98	A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. <i>Biologicals</i> , 2016, 44, 242-251.	1.4	85
99	Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets. <i>Influenza and Other Respiratory Viruses</i> , 2016, 10, 122-126.	3.4	5
100	Artesunate Demonstrates in vitro Synergism with Several Antiviral Agents against Human Cytomegalovirus. <i>Antiviral Therapy</i> , 2016, 21, 535-539.	1.0	36
101	Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2120-2127.	3.9	26
102	Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories. <i>Vaccine Journal</i> , 2016, 23, 236-242.	3.1	55
103	Both Cerebral and Hematopoietic Deficiencies in CCR2 Result in Uncontrolled Herpes Simplex Virus Infection of the Central Nervous System in Mice. <i>PLoS ONE</i> , 2016, 11, e0168034.	2.5	8
104	Innate immune response during herpes simplex virus encephalitis and development of immunomodulatory strategies. <i>Reviews in Medical Virology</i> , 2015, 25, 300-319.	8.3	35
105	Effect of In Vitro Syncytium Formation on the Severity of Human Metapneumovirus Disease in a Murine Model. <i>PLoS ONE</i> , 2015, 10, e0120283.	2.5	11
106	Infiltration Pattern of Blood Monocytes into the Central Nervous System during Experimental Herpes Simplex Virus Encephalitis. <i>PLoS ONE</i> , 2015, 10, e0145773.	2.5	28
107	E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. <i>Journal of Infectious Diseases</i> , 2015, 212, 1726-1734.	4.0	54
108	Contrasting Effects of W781V and W780V Mutations in Helix N of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Antiviral Drug Susceptibility. <i>Journal of Virology</i> , 2015, 89, 4636-4644.	3.4	13



#	ARTICLE	IF	CITATIONS
109	Intrahost Dynamics of Antiviral Resistance in Influenza A Virus Reflect Complex Patterns of Segment Linkage, Reassortment, and Natural Selection. <i>MBio</i> , 2015, 6, .	4.1	58
110	Adjuvant effect of the human metapneumovirus (HMPV) matrix protein in HMPV subunit vaccines. <i>Journal of General Virology</i> , 2015, 96, 767-774.	2.9	11
111	Heterosubtypic Protection Conferred by the Human Monoclonal Antibody PN-SIA28 against Influenza A Virus Lethal Infections in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2647-2653.	3.2	2
112	Optimization of Droplet Digital PCR from RNA and DNA extracts with direct comparison to RT-qPCR: Clinical implications for quantification of Oseltamivir-resistant subpopulations. <i>Journal of Virological Methods</i> , 2015, 224, 58-66.	2.1	107
113	Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone. <i>Antiviral Research</i> , 2015, 123, 105-113.	4.1	38
114	Cytomegalovirus quantification in plasma with Abbott RealTime CMV and Roche Cobas Amplicor CMV assays. <i>Journal of Virological Methods</i> , 2015, 225, 1-3.	2.1	9
115	Targeted Proteomics of Human Metapneumovirus in Clinical Samples and Viral Cultures. <i>Analytical Chemistry</i> , 2015, 87, 10247-10254.	6.5	35
116	Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains. <i>Antiviral Research</i> , 2015, 114, 57-61.	4.1	14
117	Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility. <i>PLoS ONE</i> , 2015, 10, e0126115.	2.5	46
118	Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4043-4046.	3.9	26
119	Antiviral Drug Resistance in Herpesviruses. , 2014, , 1-32.		0
120	Phenotypic Evaluation of Previously Uncharacterized Cytomegalovirus DNA Polymerase Sequence Variants Detected in a Valganciclovir Treatment Trial. <i>Journal of Infectious Diseases</i> , 2014, 209, 1219-1226.	4.0	26
121	Antiviral drug resistance in herpesviruses other than cytomegalovirus. <i>Reviews in Medical Virology</i> , 2014, 24, 186-218.	8.3	115
122	Oseltamivir+zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. <i>Antiviral Research</i> , 2014, 105, 54-58.	4.1	13
123	Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A(H1N1)pdm09 Virus<i> In Vitro</i>, in Mice and in Ferrets. <i>Journal of Virology</i> , 2014, 88, 1652-1658.	3.4	44
124	Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines. <i>Vaccine</i> , 2014, 32, 5730-5739.	3.8	13
125	Evolution of Oseltamivir Resistance Mutations in Influenza A(H1N1) and A(H3N2) Viruses during Selection in Experimentally Infected Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6398-6405.	3.2	26
126	Epitope mapping of the 2009 pandemic and the A/Brisbane/59/2007 seasonal (H1N1) influenza virus haemagglutinins using mAbs and escape mutants. <i>Journal of General Virology</i> , 2014, 95, 2377-2389.	2.9	15



#	ARTICLE	IF	CITATIONS
127	Characterization of Drug-Resistant Influenza Virus A(H1N1) and A(H3N2) Variants Selected In Vitro with Laninamivir. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5220-5228.	3.2	41
128	Human metapneumovirus viral load is an important risk factor for disease severity in young children. <i>Journal of Clinical Virology</i> , 2014, 60, 133-140.	3.1	28
129	Randomized Controlled Ferret Study to Assess the Direct Impact of 2008-09 Trivalent Inactivated Influenza Vaccine on A(H1N1)pdm09 Disease Risk. <i>PLoS ONE</i> , 2014, 9, e86555.	2.5	19
130	Recent developments with live-attenuated recombinant paramyxovirus vaccines. <i>Reviews in Medical Virology</i> , 2013, 23, 15-34.	8.3	23
131	Genetic diversity and molecular evolution of the major human metapneumovirus surface glycoproteins over a decade. <i>Journal of Clinical Virology</i> , 2013, 58, 541-547.	3.1	41
132	Host and Viral Factors Affecting Clinical Performance of a Rapid Diagnostic Test for Respiratory Syncytial Virus in Hospitalized Children. <i>Journal of Pediatrics</i> , 2013, 163, 911-913.	1.8	24
133	Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir. <i>Journal of Clinical Virology</i> , 2013, 58, 279-282.	3.1	11
134	Influenza virus resistance to neuraminidase inhibitors. <i>Antiviral Research</i> , 2013, 98, 174-185.	4.1	300
135	Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice. <i>Vaccine</i> , 2013, 31, 2778-2785.	3.8	41
136	Detection and management of antiviral resistance for influenza viruses. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 18-23.	3.4	50
137	The combination of valacyclovir with an anti-TNF alpha antibody increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis. <i>Antiviral Research</i> , 2013, 100, 649-653.	4.1	19
138	Emergence of an Oseltamivir-Resistant Influenza A/H3N2 Virus in an Elderly Patient Receiving a Suboptimal Dose of Antiviral Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2013, 51, 4234-4236.	3.9	9
139	Evaluation of Epstein-Barr Virus, Human Herpesvirus 6 (HHV-6), and HHV-8 Antiviral Drug Susceptibilities by Use of Real-Time-PCR-Based Assays. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1244-1246.	3.9	11
140	Both TRIF and IPS-1 Adaptor Proteins Contribute to the Cerebral Innate Immune Response against Herpes Simplex Virus 1 Infection. <i>Journal of Virology</i> , 2013, 87, 7301-7308.	3.4	30
141	Evaluation of Recombinant 2009 Pandemic Influenza A (H1N1) Viruses Harboring Zanamivir Resistance Mutations in Mice and Ferrets. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1784-1789.	3.2	15
142	Reply to "Calibration Technologies for Correct Determination of Epstein-Barr Virus, Human Herpesvirus 6 (HHV-6), and HHV-8 Antiviral Drug Susceptibilities by Use of Real-Time-PCR-Based Assays". <i>Journal of Clinical Microbiology</i> , 2013, 51, 2014-2014.	3.9	0
143	Novel Method Based on In Passant Mutagenesis Coupled with a Gaussia Luciferase Reporter Assay for Studying the Combined Effects of Human Cytomegalovirus Mutations. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3216-3224.	3.9	30
144	Modulation of Protease Activated Receptor 1 Influences Human Metapneumovirus Disease Severity in a Mouse Model. <i>PLoS ONE</i> , 2013, 8, e72529.	2.5	33

#	ARTICLE	IF	CITATIONS
145	Comparison of Risk Factors for Human Metapneumovirus and Respiratory Syncytial Virus Disease Severity in Young Children. <i>Journal of Infectious Diseases</i> , 2012, 206, 178-189.	4.0	122
146	Cross-reactive and Vaccine-Induced Antibody to an Emerging Swine-Origin Variant of Influenza A Virus Subtype H3N2 (H3N2v). <i>Journal of Infectious Diseases</i> , 2012, 206, 1852-1861.	4.0	82
147	Presence of Oseltamivir-Resistant Pandemic A/H1N1 Minor Variants Before Drug Therapy With Subsequent Selection and Transmission. <i>Journal of Infectious Diseases</i> , 2012, 206, 1504-1511.	4.0	70
148	Effects of Different Adjuvants in the Context of Intramuscular and Intranasal Routes on Humoral and Cellular Immune Responses Induced by Detergent-Split A/H3N2 Influenza Vaccines in Mice. <i>Vaccine Journal</i> , 2012, 19, 209-218.	3.1	42
149	The H275Y Neuraminidase Mutation of the Pandemic A/H1N1 Influenza Virus Lengthens the Eclipse Phase and Reduces Viral Output of Infected Cells, Potentially Compromising Fitness in Ferrets. <i>Journal of Virology</i> , 2012, 86, 10651-10660.	3.4	99
150	Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4375-4380.	3.2	16
151	Impact of deficiency in CCR2 and CX3CR1 receptors on monocytes trafficking in herpes simplex virus encephalitis. <i>Journal of General Virology</i> , 2012, 93, 1294-1304.	2.9	24
152	Modulation of TLR9 response in a mouse model of herpes simplex virus encephalitis. <i>Antiviral Research</i> , 2012, 96, 414-421.	4.1	24
153	Molecular and antigenic evolution of human influenza A/H3N2 viruses in Quebec, Canada, 2009-2011. <i>Journal of Clinical Virology</i> , 2012, 53, 88-92.	3.1	24
154	Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. <i>Journal of Clinical Virology</i> , 2012, 53, 208-213.	3.1	46
155	Cross-Lineage Influenza B and Heterologous Influenza A Antibody Responses in Vaccinated Mice: Immunologic Interactions and B/Yamagata Dominance. <i>PLoS ONE</i> , 2012, 7, e38929.	2.5	40
156	Seroconversion to Seasonal Influenza Viruses after A(H1N1)pdm09 Virus Infection, Quebec, Canada. <i>Emerging Infectious Diseases</i> , 2012, 18, 1132-4.	4.3	6
157	Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006-2010. <i>Emerging Infectious Diseases</i> , 2012, 18, 120-124.	4.3	31
158	Impact of Mutations at Residue I223 of the Neuraminidase Protein on the Resistance Profile, Replication Level, and Virulence of the 2009 Pandemic Influenza Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1208-1214.	3.2	53
159	Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. <i>Vaccine</i> , 2011, 30, 35-41.	3.8	36
160	Parenteral Peramivir Treatment for Oseltamivir-Resistant 2009 Pandemic Influenza A H1N1 Viruses. <i>Journal of Infectious Diseases</i> , 2011, 204, 1641-1642.	4.0	11
161	Assessing the In Vitro Fitness of an Oseltamivir-Resistant Seasonal A/H1N1 Influenza Strain Using a Mathematical Model. <i>PLoS ONE</i> , 2011, 6, e14767.	2.5	54
162	Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets. <i>Antiviral Therapy</i> , 2011, 16, 775-779.	1.0	16

#	ARTICLE	IF	CITATIONS
163	Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. <i>Influenza and Other Respiratory Viruses</i> , 2011, 5, 247-255.	3.4	91
164	Systematic review of influenza resistance to the neuraminidase inhibitors. <i>BMC Infectious Diseases</i> , 2011, 11, 134.	2.9	171
165	Generation and Characterization of Recombinant Pandemic Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors. <i>Journal of Infectious Diseases</i> , 2011, 203, 25-31.	4.0	136
166	Influenza Drug Resistance. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 409-422.	2.1	69
167	The I222V Neuraminidase Mutation Has a Compensatory Role in Replication of an Oseltamivir-Resistant Influenza Virus A/H3N2 E119V Mutant. <i>Journal of Clinical Microbiology</i> , 2011, 49, 715-717.	3.9	38
168	Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4019-4027.	3.2	28
169	Long-term impairment of <i>Streptococcus pneumoniae</i> lung clearance is observed after initial infection with influenza A virus but not human metapneumovirus in mice. <i>Journal of General Virology</i> , 2011, 92, 1662-1665.	2.9	12
170	Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 459-472.	3.2	428
171	Design considerations in building <i>in silico</i> equivalents of common experimental influenza virus assays. <i>Autoimmunity</i> , 2011, 44, 282-293.	2.6	30
172	Role of Permissive Neuraminidase Mutations in Influenza A/Brisbane/59/2007-like (H1N1) Viruses. <i>PLoS Pathogens</i> , 2011, 7, e1002431.	4.7	71
173	Evaluation of Serological Diagnostic Methods for the 2009 Pandemic Influenza A (H1N1) Virus. <i>Vaccine Journal</i> , 2011, 18, 520-522.	3.1	19
174	The 2009 Pandemic H1N1 D222G Hemagglutinin Mutation Alters Receptor Specificity and Increases Virulence in Mice but Not in Ferrets. <i>Journal of Infectious Diseases</i> , 2011, 204, 1008-1016.	4.0	38
175	Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis. <i>Transplantation</i> , 2010, 90, 1409-1413.	1.0	22
176	Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity. <i>Antiviral Therapy</i> , 2010, 15, 579-586.	1.0	17
177	Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. <i>Antiviral Research</i> , 2010, 88, 31-37.	4.1	33
178	Neurovirulence and latency of drug-resistant clinical herpes simplex viruses in animal models. <i>Journal of Medical Virology</i> , 2010, 82, 1000-1006.	5.0	15
179	The distinguishing features of human metapneumovirus and respiratory syncytial virus. <i>Reviews in Medical Virology</i> , 2010, 20, 245-260.	8.3	73
180	Effect of the Neuraminidase Mutation H274Y Conferring Resistance to Oseltamivir on the Replicative Capacity and Virulence of Old and Recent Human Influenza A(H1N1) Viruses. <i>Journal of Infectious Diseases</i> , 2010, 201, 740-745.	4.0	116

#	ARTICLE	IF	CITATIONS
181	Prophylactic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H274Y Neuraminidase Mutation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2819-2822.	3.2	19
182	Household Transmission of the 2009 Pandemic A/H1N1 Influenza Virus: Elevated Laboratory-Confirmed Secondary Attack Rates and Evidence of Asymptomatic Infections. <i>Clinical Infectious Diseases</i> , 2010, 51, 1033-1041.	5.8	102
183	Viral Pathogens Including Human Metapneumovirus Are the Primary Cause of Febrile Respiratory Illness in HIV-Infected Adults Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 201, 297-301.	4.0	25
184	Association between the 2008-09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring-Summer 2009: Four Observational Studies from Canada. <i>PLoS Medicine</i> , 2010, 7, e1000258.	8.4	266
185	Oseltamivir-Resistant Pandemic A/H1N1 Virus Is as Virulent as Its Wild-Type Counterpart in Mice and Ferrets. <i>PLoS Pathogens</i> , 2010, 6, e1001015.	4.7	85
186	Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. <i>Journal of Clinical Virology</i> , 2010, 47, 321-324.	3.1	34
187	Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene. <i>Journal of Clinical Virology</i> , 2010, 49, 296-298.	3.1	16
188	Activity of the Oral Neuraminidase Inhibitor A-322278 against the Oseltamivir-Resistant H274Y (A/H1N1) Influenza Virus Mutant in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 791-793.	3.2	14
189	A Novel Neuraminidase Deletion Mutation Conferring Resistance to Oseltamivir in Clinical Influenza A/H3N2 Virus. <i>Journal of Infectious Diseases</i> , 2009, 199, 180-183.	4.0	37
190	Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis. <i>New England Journal of Medicine</i> , 2009, 361, 2296-2297.	27.0	204
191	Comparison of Automated Microarray Detection with Real-Time PCR Assays for Detection of Respiratory Viruses in Specimens Obtained from Children. <i>Journal of Clinical Microbiology</i> , 2009, 47, 743-750.	3.9	88
192	Infection with Human Metapneumovirus Predisposes Mice to Severe Pneumococcal Pneumonia. <i>Journal of Virology</i> , 2009, 83, 1341-1349.	3.4	72
193	Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. <i>Journal of Clinical Virology</i> , 2009, 46, 129-133.	3.1	94
194	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. <i>Antiviral Therapy</i> , 2009, 14, 697-704.	1.0	23
195	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. <i>Antiviral Therapy</i> , 2009, 14, 697-704.	1.0	86
196	Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. <i>Antiviral Research</i> , 2008, 77, 163-166.	4.1	59
197	Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. <i>Journal of Clinical Virology</i> , 2008, 42, 52-57.	3.1	37
198	Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. <i>Vaccine</i> , 2008, 26, 3395-3403.	3.8	172

#	ARTICLE	IF	CITATIONS
199	Effect of Pretreatment with Toll-like Receptor Agonists in a Mouse Model of Herpes Simplex Virus Type 1 Encephalitis. <i>Journal of Infectious Diseases</i> , 2008, 198, 664-672.	4.0	59
200	Identification and Evaluation of a Highly Effective Fusion Inhibitor for Human Metapneumovirus. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 279-287.	3.2	51
201	Inhibition of Human Metapneumovirus Replication by Small Interfering RNA. <i>Antiviral Therapy</i> , 2008, 13, 821-832.	1.0	21
202	The Prophylactic Administration of a Monoclonal Antibody against Human Metapneumovirus Attenuates viral Disease and Airways Hyperresponsiveness in Mice. <i>Antiviral Therapy</i> , 2008, 13, 39-46.	1.0	25
203	Tumor Necrosis Factor- $\alpha$ and Interleukin-1 $\beta$ Play a Critical Role in the Resistance against Lethal Herpes Simplex Virus Encephalitis. <i>Journal of Infectious Diseases</i> , 2007, 196, 853-860.	4.0	135
204	Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. <i>Journal of General Virology</i> , 2007, 88, 3391-3400.	2.9	48
205	An Outbreak of Severe Respiratory Tract Infection Due to Human Metapneumovirus in a Long-Term Care Facility. <i>Clinical Infectious Diseases</i> , 2007, 44, 1152-1158.	5.8	183
206	Delayed but Not Early Glucocorticoid Treatment Protects the Host during Experimental Herpes Simplex Virus Encephalitis in Mice. <i>Journal of Infectious Diseases</i> , 2007, 195, 817-825.	4.0	69
207	Human metapneumovirus: Enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. <i>Vaccine</i> , 2007, 25, 5034-5040.	3.8	53
208	Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. <i>Antiviral Research</i> , 2007, 74, 159-162.	4.1	61
209	Influenza virus susceptibility and resistance to oseltamivir. <i>Antiviral Therapy</i> , 2007, 12, 603-16.	1.0	74
210	Influenza Virus Susceptibility and Resistance to Oseltamivir. <i>Antiviral Therapy</i> , 2007, 12, 603-616.	1.0	152
211	Role of Helix P of the Human Cytomegalovirus DNA Polymerase in Resistance and Hypersusceptibility to the Antiviral Drug Foscarnet. <i>Journal of Virology</i> , 2006, 80, 1440-1450.	3.4	28
212	Longitudinal evaluation of herpes simplex virus DNA load during episodes of herpes labialis. <i>Journal of Clinical Virology</i> , 2006, 37, 248-251.	3.1	21
213	Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. <i>Proteins: Structure, Function and Bioinformatics</i> , 2006, 64, 301-307.	2.6	20
214	Treatment of respiratory virus infections. <i>Antiviral Research</i> , 2006, 70, 1-16.	4.1	64
215	Distribution and Clinical Impact of Human Respiratory Syncytial Virus Genotypes in Hospitalized Children over 2 Winter Seasons. <i>Journal of Infectious Diseases</i> , 2006, 193, 54-58.	4.0	87
216	Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome. <i>Journal of Infectious Diseases</i> , 2006, 194, 579-583.	4.0	25

#	ARTICLE	IF	CITATIONS
217	Effect of Ribavirin and Glucocorticoid Treatment in a Mouse Model of Human Metapneumovirus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 774-777.	3.2	106
218	Thymidine Kinase Mutations Conferring Acyclovir Resistance in Herpes Simplex Type 1 Recombinant Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3889-3892.	3.2	22
219	Human Metapneumovirus Infection Induces Long-Term Pulmonary Inflammation Associated with Airway Obstruction and Hyperresponsiveness in Mice. <i>Journal of Infectious Diseases</i> , 2006, 193, 1634-1642.	4.0	87
220	Characterization of Multidrug-Resistant Influenza A/H3N2 Viruses Shed during 1 Year by an Immunocompromised Child. <i>Clinical Infectious Diseases</i> , 2006, 43, 1555-1561.	5.8	174
221	Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. <i>Antiviral Therapy</i> , 2006, 11, 971-6.	1.0	81
222	Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds. <i>Antiviral Therapy</i> , 2006, 11, 971-976.	1.0	155
223	A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 1462-1468.	4.7	89
224	Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. <i>Journal of Medical Virology</i> , 2005, 77, 425-429.	5.0	60
225	Pathogenesis of Human Metapneumovirus Lung Infection in BALB/c Mice and Cotton Rats. <i>Journal of Virology</i> , 2005, 79, 8894-8903.	3.4	99
226	Generation and Characterization of Recombinant Influenza A (H1N1) Viruses Harboring Amantadine Resistance Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 556-559.	3.2	169
227	Global Genetic Diversity of Human Metapneumovirus Fusion Gene. <i>Emerging Infectious Diseases</i> , 2004, 10, 1154-1157.	4.3	122
228	Sequence polymorphism of the predicted human metapneumovirus G glycoprotein. <i>Journal of General Virology</i> , 2004, 85, 679-686.	2.9	62
229	Absence of Cytomegalovirus-Resistance Mutations after Valganciclovir Prophylaxis, in a Prospective Multicenter Study of Solid-Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2004, 189, 1615-1618.	4.0	158
230	Human Metapneumovirus: A New Player among Respiratory Viruses. <i>Clinical Infectious Diseases</i> , 2004, 38, 983-990.	5.8	167
231	A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. <i>Antiviral Therapy</i> , 2004, 9, 577-81.	1.0	35
232	A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus. <i>Antiviral Therapy</i> , 2004, 9, 577-581.	1.0	75
233	Genetic diversity between human metapneumovirus subgroups. <i>Virology</i> , 2003, 315, 1-9.	2.4	219
234	Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. <i>Antiviral Research</i> , 2003, 60, 51-59.	4.1	186



#	ARTICLE	IF	CITATIONS
235	Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains. <i>Virus Research</i> , 2003, 93, 51-62.	2.2	112
236	Evaluation of Susceptibility of Human Herpesvirus 8 to Antiviral Drugs by Quantitative Real-Time PCR. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3897-3900.	3.9	37
237	Comparative Evaluation of Real-Time PCR Assays for Detection of the Human Metapneumovirus. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3631-3635.	3.9	117
238	Discordant phenotypes and genotypes of Cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. <i>Aids</i> , 2003, 17, 337-341.	2.2	19
239	Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids. <i>Journal of Virology</i> , 2003, 77, 7820-7829.	3.4	82
240	Human Metapneumovirus Infections in Hospitalized Children <sup>1</sup> . <i>Emerging Infectious Diseases</i> , 2003, 9, 634-640.	4.3	395
241	Characterization of 2 Influenza A(H3N2) Clinical Isolates with Reduced Susceptibility to Neuraminidase Inhibitors Due to Mutations in the Hemagglutinin Gene. <i>Journal of Infectious Diseases</i> , 2002, 186, 1074-1080.	4.0	57
242	Prolonged Excretion of Amantadine-Resistant Influenza A Virus Quasi Species after Cessation of Antiviral Therapy in an Immunocompromised Patient. <i>Clinical Infectious Diseases</i> , 2002, 34, e23-e25.	5.8	73
243	Role of Picornaviruses in Flu-Like Illnesses of Adults Enrolled in an Oseltamivir Treatment Study Who Had No Evidence of Influenza Virus Infection. <i>Journal of Clinical Microbiology</i> , 2002, 40, 330-334.	3.9	19
244	Virological Features and Clinical Manifestations Associated with Human Metapneumovirus: A New Paramyxovirus Responsible for Acute Respiratory Tract Infections in All Age Groups. <i>Journal of Infectious Diseases</i> , 2002, 186, 1330-1334.	4.0	527
245	Characterization of Human Metapneumoviruses Isolated from Patients in North America. <i>Journal of Infectious Diseases</i> , 2002, 185, 1660-1663.	4.0	362
246	Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. <i>Drug Resistance Updates</i> , 2002, 5, 88-114.	14.4	277
247	Respiratory Tract Reinfections by the New Human Metapneumovirus in an Immunocompromised Child. <i>Emerging Infectious Diseases</i> , 2002, 8, 976-978.	4.3	207
248	Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. <i>Antiviral Research</i> , 2002, 54, 143-147.	4.1	64
249	Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada. <i>Journal of Medical Virology</i> , 2002, 67, 589-595.	5.0	39
250	Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. <i>Journal of Medical Virology</i> , 2002, 68, 399-403.	5.0	40
251	Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. <i>Journal of Medical Virology</i> , 2002, 67, 88-91.	5.0	28
252	Intranasal herpes simplex virus type 2 inoculation causes a profound thymidine kinase dependent cerebral inflammatory response in the mouse hindbrain. <i>European Journal of Neuroscience</i> , 2002, 16, 29-43.	2.6	46



#	ARTICLE	IF	CITATIONS
253	Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues. <i>Journal of Virology</i> , 2001, 75, 3105-3110.	3.4	56
254	Rate of Emergence of Cytomegalovirus (CMV) Mutations in Leukocytes of Patients with Acquired Immunodeficiency Syndrome Who Are Receiving Valganciclovir as Induction and Maintenance Therapy for CMV Retinitis. <i>Journal of Infectious Diseases</i> , 2001, 184, 1598-1602.	4.0	124
255	Rapid Antiviral Effect of Inhaled Zanamivir in the Treatment of Naturally Occurring Influenza in Otherwise Healthy Adults. <i>Journal of Infectious Diseases</i> , 2000, 181, 1471-1474.	4.0	73
256	Characterization of the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Isolates from AIDS Patients in whom Acyclovir and Foscarnet Therapy Sequentially Failed. <i>Journal of Infectious Diseases</i> , 1999, 180, 487-490.	4.0	92
257	Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. <i>Aids</i> , 1998, 12, 125-129.	2.2	45
258	Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications. <i>Clinical Microbiology Reviews</i> , 1998, 11, 533-554.	13.6	376
259	Antiviral Susceptibilities and Analysis of UL97 and DNA Polymerase Sequences of Clinical Cytomegalovirus Isolates from Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 1997, 175, 1087-1092.	4.0	148
260	A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS. <i>Aids</i> , 1997, 11, 867-873.	2.2	22
261	Diagnosis of Viral Infections. , 0, , 291-319.		5